Current location - Trademark Inquiry Complete Network - Trademark inquiry - Patent number query: ZL 03 1 39050.1
Patent number query: ZL 03 1 39050.1

Application (patent) number: 03139050.1 Large, medium and small

Application disclosure instructions (6) pages Approval authorization instructions (6) pages Application number: 03139050.1 Application date: 2003.09.16

Name: A drug for treating avascular necrosis of the femoral head

Publication (announcement) number: CN1524565 Publication (announcement) date: 2004.09.01

Main classification number : A61K35/78 Divisional original application number:

Classification number: A61K35/78;A61K9/14;A61P19/08

Issue date: Priority:

< p>Applicant (patent right): Qiao Shihua

Address: No. 43, Gulou North Street, Liaocheng City, Shandong Province 252000

Inventor (designer): Qiao Shihua International application:

International announcement: Date of entry into the country:

Patent agency: Jinan Chengzhi Trademark and Patent Office Co., Ltd. Agent: Wang Ruyin

Summary

This The invention discloses a medicine for treating avascular necrosis of the femoral head, which is a traditional Chinese medicine preparation using Chinese herbal medicine as raw material for treating the necrosis of the femoral head. The specific plan adopted is: this drug for treating avascular necrosis of the femoral head is characterized by having the following components by weight: 40-60 parts by weight of turtle plate, 40-60 parts of blood-curing blood, 40-60 parts of antler glue, and 40 parts of pangolin. -60, Ligusticum chuanxiong 40-60, Angelica sinensis 40-60, Safflower 40-60, Rehmannia glutinosa 40-60; the above components are screened, cleaned, disinfected, dried, crushed, and synthesized into traditional Chinese medicine preparations. The clinical use of this drug shows that using the comprehensive effect of a variety of traditional Chinese medicines to treat femoral head necrosis has little toxic and side effects on the human body. No toxic or side effects have been found in animal tests. 162 cases were followed clinically, with a significant rate of 88% and an effective rate of 92%. For the treatment of avascular necrosis of the femoral head.